Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Aug. 31, 2017 | Oct. 16, 2017 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Aug. 31, 2017 | |
Trading Symbol | orgs | |
Entity Registrant Name | Orgenesis Inc. | |
Entity Central Index Key | 1,460,602 | |
Current Fiscal Year End Date | --11-30 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 121,779,252 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well Known Seasoned Issuer | No | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q3 |
CONDENSED CONSOLIDATED BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Aug. 31, 2017 | Nov. 30, 2016 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 762 | $ 891 |
Accounts receivable, net | 2,106 | 1,229 |
Prepaid expenses and other receivables | 1,668 | 779 |
Grants receivable | 173 | 906 |
Inventory | 965 | 400 |
Total current assets | 5,674 | 4,205 |
NON CURRENT ASSETS: | ||
Property and equipment, net | 5,025 | 4,573 |
Restricted cash | 6 | 5 |
Intangible assets, net | 15,480 | 15,050 |
Goodwill | 10,683 | 9,584 |
Investments in associate, net | 475 | 0 |
Other assets | 79 | 70 |
Total non-current assets | 31,748 | 29,282 |
TOTAL ASSETS | 37,422 | 33,487 |
CURRENT LIABILITIES: | ||
Short-term bank credit | 0 | 21 |
Accounts payable | 3,689 | 4,554 |
Accrued expenses and other payables | 1,408 | 1,205 |
Employees and related payables | 2,343 | 1,680 |
Related parties | 44 | 42 |
Advance payments on account of grant | 1,978 | 243 |
Short-term loans and current maturities of long term loans | 376 | 1,111 |
Deferred income | 4,944 | 1,273 |
Current maturities of convertible loans | 2,789 | 2,541 |
Convertible bonds | 0 | 1,818 |
Price protection derivative | 0 | 76 |
Investments in associate, net | 0 | 12 |
TOTAL CURRENT LIABILITIES | 17,571 | 14,576 |
LONG-TERM LIABILITIES: | ||
Loans payable | 3,397 | 3,291 |
Convertible loans | 1,444 | 1,059 |
Warrants | 873 | 1,843 |
Retirement benefits obligation | 5 | 5 |
Put option derivative | 273 | 273 |
Deferred taxes | 2,608 | 1,862 |
TOTAL LONG-TERM LIABILITIES | 8,600 | 8,333 |
TOTAL LIABILITIES | 26,171 | 22,909 |
COMMITMENTS | 0 | 0 |
EQUITY: | ||
Common stock | 12 | 12 |
Additional paid-in capital | 50,518 | 41,605 |
Receipts on account of shares to be allotted | 852 | 0 |
Accumulated other comprehensive loss | 1,214 | (1,205) |
Accumulated deficit | (41,345) | (29,834) |
TOTAL EQUITY | 11,251 | 10,578 |
TOTAL LIABILITIES AND EQUITY | $ 37,422 | $ 33,487 |
CONDENSED CONSOLIDATED STATEMEN
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
Aug. 31, 2017 | Aug. 31, 2016 | Aug. 31, 2017 | Aug. 31, 2016 | |
REVENUES | $ 2,562 | $ 1,849 | $ 6,712 | $ 4,501 |
COST OF REVENUES | 1,867 | 1,829 | 4,900 | 5,273 |
GROSS PROFIT (LOSS) | 695 | 20 | 1,812 | (772) |
RESEARCH AND DEVELOPMENT EXPENSES, net | 500 | 775 | 1,906 | 1,663 |
AMORTIZATION OF INTANGIBLE ASSETS | 423 | 408 | 1,201 | 1,217 |
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES | 3,184 | 1,279 | 7,887 | 4,618 |
OPERATING LOSS | 3,412 | 2,442 | 9,182 | 8,270 |
FINANCIAL EXPENSES (INCOME), net | (2,032) | 574 | 1,488 | (645) |
SHARE IN LOSSES OF ASSOCIATED COMPANY | 152 | 0 | 348 | 0 |
LOSS BEFORE INCOME TAXES | 1,532 | 3,016 | 11,018 | 7,625 |
TAX EXPENSES (BENEFIT) | 421 | (372) | 493 | (1,313) |
NET LOSS | $ 1,953 | $ 2,644 | $ 11,511 | $ 6,312 |
EARNINGS (LOSS) PER SHARE: | ||||
Basic | $ (0.02) | $ (0.02) | $ (0.10) | $ (0.06) |
Diluted | $ (0.02) | $ (0.02) | $ (0.10) | $ (0.06) |
WEIGHTED AVERAGE NUMBER OF SHARES USED IN COMPUTATION OF BASIC AND DILUTED EARNINGS (LOSS) PER SHARE: | ||||
Basic | 123,349,597 | 111,188,616 | 113,433,712 | 108,784,862 |
Diluted | 124,625,412 | 111,188,616 | 113,746,212 | 108,784,862 |
OTHER COMPREHENSIVE LOSS: | ||||
Net Loss | $ 1,953 | $ 2,644 | $ 11,511 | $ 6,312 |
Translation adjustments | (1,430) | 36 | (2,419) | (1,047) |
TOTAL COMPREHENSIVE LOSS | $ 523 | $ 2,680 | $ 9,092 | $ 5,265 |
CONDENSED CONSOLIDATED STATEME4
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands | Common Stock [Member] | Additional Paid-in Capital [Member] | Receipts on Account of Share to be Allotted [Member] | Accumulated Other Comprehensive Loss[Member] | Accumulated Deficit [Member] | Total |
Beginning Balance at Nov. 30, 2015 | $ 6 | $ 14,229 | $ 1,251 | $ (1,286) | $ (20,640) | $ (6,440) |
Beginning Balance (Shares) at Nov. 30, 2015 | 55,835,950 | |||||
Stock-based compensation to employees and directors | 990 | 990 | ||||
Stock-based compensation to service providers | 1,148 | 1,148 | ||||
Warrants and shares to be issued due to extinguishment of a convertible loan | 114 | 114 | ||||
Beneficial conversion feature of convertible loans | 245 | 245 | ||||
Issuance of shares from investments and conversion of convertible loans | $ 1 | 1,948 | (1,251) | 698 | ||
Issuance of shares from investments and conversion of convertible loans (Shares) | 12,844,455 | |||||
Reclassification of redeemable common stock | $ 4 | 21,454 | 21,458 | |||
Reclassification of redeemable common stock (Shares) | 42,401,724 | |||||
Receipts on account of shares to be allotted | 887 | 887 | ||||
Comprehensive income (loss) for the period | 1,047 | (6,312) | (5,265) | |||
Ending Balance at Aug. 31, 2016 | $ 11 | 40,128 | 887 | (239) | (26,952) | 13,835 |
Ending Balance (Shares) at Aug. 31, 2016 | 111,082,129 | |||||
Beginning Balance at Nov. 30, 2016 | $ 12 | 41,605 | (1,205) | (29,834) | 10,578 | |
Beginning Balance (Shares) at Nov. 30, 2016 | 114,096,461 | |||||
Stock-based compensation to employees and directors | 1,156 | 1,156 | ||||
Stock-based compensation to service providers | 1,824 | 1,824 | ||||
Stock-based compensation to service providers (Shares) | 950,000 | |||||
Issuance of warrants and beneficial conversion feature of convertible loans | 2,550 | 2,550 | ||||
Issuance of shares and receipts on account of shares and warrants to be allotted and cancelation of contingent shares | 3,383 | 852 | 4,235 | |||
Issuance of shares and receipts on account of shares and warrants to be allotted and cancelation of contingent shares (Shares) | 2,936,918 | |||||
Comprehensive income (loss) for the period | 2,419 | (11,511) | (9,092) | |||
Ending Balance at Aug. 31, 2017 | $ 12 | $ 50,518 | $ 852 | $ 1,214 | $ (41,345) | $ 11,251 |
Ending Balance (Shares) at Aug. 31, 2017 | 117,983,379 |
CONDENSED CONSOLIDATED STATEME5
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands | 9 Months Ended | |
Aug. 31, 2017 | Aug. 31, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (11,511) | $ (6,312) |
Adjustments required to reconcile net loss to net cash used in operating activities: | ||
Stock-based compensation | 2,817 | 2,085 |
Loss from extinguishment of a convertible loan | 0 | 229 |
Share in losses of associated company | 348 | 0 |
Depreciation and amortization expenses | 1,874 | 1,987 |
Change in fair value of warrants and embedded derivatives | (1,276) | (1,172) |
Change in fair value of convertible bonds | (157) | (115) |
Interest expenses accrued on loans and convertible loans (including amortization of beneficial conversion feature) | 818 | 494 |
Changes in operating assets and liabilities: | ||
Increase in accounts receivable | (682) | (603) |
Increase in inventory | (484) | (73) |
Increase in other assets | (1) | (17) |
Increase in prepaid expenses and other accounts receivable | (818) | (220) |
Increase (decrease) in accounts payable | (1,230) | 637 |
Increase in accrued expenses and other payables | 192 | 242 |
Increase in employee and related payables | 554 | 523 |
Increase in deferred income | 3,268 | 402 |
Increase in advance payments and receivables on account of grant, net | 2,358 | 50 |
Increase (decrease) in deferred taxes | 494 | (1,314) |
Net cash used in operating activities | (3,436) | (3,177) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of property and equipment | (639) | (1,049) |
Disposals of property and equipment | 31 | 0 |
Investments in associate | (835) | 0 |
Net cash used in investing activities | (1,443) | (1,049) |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Short-term line of credit | (21) | 17 |
Proceeds from issuance of shares and warrants (net of transaction costs) | 4,307 | 1,488 |
Proceeds from issuance of convertible loans (net of transaction costs) | 4,932 | 1,258 |
Repayment of convertible loans and convertible bonds | (3,766) | 0 |
Repayment of short and long-term debt | (1,102) | (2,446) |
Net cash provided by financing activities | 4,350 | 317 |
NET CHANGE IN CASH AND CASH EQUIVALENTS | (529) | (3,909) |
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS | 400 | 11 |
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD | 891 | 4,168 |
CASH AND CASH EQUIVALENTS AT END OF PERIOD | 762 | 270 |
SUPPLEMENTAL NON-CASH FINANCING ACTIVITIES | ||
Conversion of loans and bonds (including accrued interest) to common stock and warrants | 106 | 1,028 |
Reclassification of redeemable common stock to equity | $ 0 | $ 21,458 |
GENERAL AND BASIS OF PRESENTATI
GENERAL AND BASIS OF PRESENTATION | 9 Months Ended |
Aug. 31, 2017 | |
GENERAL AND BASIS OF PRESENTATION [Text Block] | NOTE 1 - GENERAL AND BASIS OF PRESENTATION Orgenesis Inc., a Nevada corporation, is a biopharmaceutical company with expertise and experience in cell therapy development and manufacturing specializing in cell therapy development for advanced medicinal products serving the regenerative medicine industry. In addition, the Company is developing a novel and proprietary cell therapy trans-differentiation technologies for the treatment of diabetes. The cell therapy technology is based on the research work of Prof. Sarah Ferber, the Company's Chief Science Officer and a researcher at Tel Hashomer Medical Research (“THM”), a leading medical hospital and research center in Israel, who established a proof of concept that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and transdifferentiating (converting) them into “pancreatic beta cell-like” insulin-producing cells. The combination of proprietary cell therapy trans-differentiation technologies for the treatment of diabetes and a revenue-generating contract development and manufacturing service business provides the Company with unique capabilities. As used in this report and unless otherwise indicated, the term “Company” refers to Orgenesis Inc. and its subsidiaries (“Subsidiaries”). Unless otherwise specified, all amounts are expressed in United States dollars. Basis of Presentation These unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. GAAP, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, the unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of August 31, 2017, and the consolidated statements of comprehensive loss for the three and nine months ended August 31, 2017 and 2016, and the changes in equity and cash flows for the nine months period ended August 31, 2017 and 2016. The interim results, are not necessarily indicative of the results to be expected for the year ending November 30, 2017. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended November 30, 2016. Going Concern The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As of August 31, 2017, the Company had accumulated losses of approximately $41 million and expects to incur further losses in the development of its business. Presently, the Company does not have sufficient cash to meet its requirements in the following twelve months. These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to obtain additional financing as may be required and ultimately to attain profitability. In the event that the remaining subscription proceeds from a private placement with an institutional investor referred to below, in the aggregate amount of $12 million (out of total committed amount $16 million) will not be paid periodically through August 2018, then the Company will need to raise significant funds in order to continue to meet its liquidity needs, realize its business plan and maintain operations. The Company’s current cash balance is not sufficient to support its operations as presently conducted or permit it to take advantage of business opportunities that may arise. Management of the Company is continuing its efforts to generate sustainable profits from its CDMO business and to secure funds through equity and/or debt instruments for its operations and business opportunities investments. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that management will be successful in implementing its business plan or that the successful implementation of its business plan will actually improve the Company’s operating results. If the Company is unable to raise the necessary capital, the Company may have to cease curtail or reduce operations. The Company has been funding its operations primarily from the proceeds from private placements of the Company’s convertible debt and equity securities and from revenues generated by MaSTherCell. From December 2016 through August 2017, the Company received, through MaSTherCell, proceeds of approximately $6.1 million in revenues and accounts receivable from customers and $9 million from the private placement to accredited investors of its equity and equity linked securities and convertible loans, out of which $3.5 are million from the institutional investor definitive agreements in January 2017 for the private placement of units of the Company’s securities for aggregate subscription proceeds to the Company of $16 million. The subscription proceeds are payable on a periodic basis through August 2018. In addition, from September 1, 2017 through October 16, 2017, the Company raised an additional $1.1 million from the proceeds of the private placement to certain accredited investors of its equity and equity linked securities and Company received, through MaSTherCell, proceeds of approximately $1 million in accounts receivable from its customers. |
SUMMARY OF SIGNIFICANT ACCOUNTI
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | 9 Months Ended |
Aug. 31, 2017 | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Text Block] | NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The accounting policies adopted are consistent with those of the previous financial year. |
SEGMENT INFORMATION
SEGMENT INFORMATION | 9 Months Ended |
Aug. 31, 2017 | |
SEGMENT INFORMATION [Text Block] | NOTE 3 - SEGMENT INFORMATION The Chief Executive Officer ("CEO") is the Company’s chief operating decision-maker ("CODM"). Based on the Company's organizational structure, its business activities and information reviewed by the CODM for the purposes of allocating resources and assessing performance, management has determined that there are two operating segments. CDMO The CDMO activity is comprised of a specialization in cell therapy development for advanced therapeutic products and is comprised of two types of services to its customers: (i) process and assay development services and (ii) cGMP contract manufacturing services. The CDMO activities include the operations of MaSTherCell. CTB The Cellular Therapy Business (“CTB”) activity is based on the technology licensed by the Israeli Subsidiary, that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into “pancreatic beta cell-like” insulin producing cells for patients with Type 1 Diabetes. The Company assesses the performance based on a measure of "Adjusted EBIT" (earnings before financial expenses and tax, and excluding share-based compensation expenses and non-recurring income or expenses). The measure of assets has not been disclosed for each segment. Segment data for the nine months ended August 31, 2017 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Revenues from external customers $ 7,705 (993 ) $ 6,712 Cost of revenues (4,358 ) 403 (3,955 ) Research and development expenses, net (1,932 ) 590 (1,342 ) Operating expenses (916 ) (6,060 ) (6,976 ) Depreciation and amortization expenses (2,145 ) (7 ) (2,152 ) Segment Performance $ 286 (8,000 ) - (7,714 ) Stock-based compensation (2,817 ) (2,817 ) Financial expenses , net* (139 ) (139 ) Share in losses of associated company (348 ) (348 ) Loss before income taxes (11,018 ) * Excluding $1,389 thousand stock based compensation included in financial expenses. Segment data for the nine months ended August 31, 2016 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 4,826 $ $ (325 ) $ 4,501 Cost of revenues (4,968 ) 463 (4,505 ) Research and development expenses, net (1,239 ) (138 ) (1,377 ) Operating expenses (1,518 ) (1,299 ) (2,817 ) Depreciation and amortization expense (1,984 ) (3 ) (1,987 ) Segment Performance $ (3,644 ) $ (2,541 ) - (6,185 ) Share-based compensation (2,085 ) (2,085 ) Financial income, net 645 645 Loss before income taxes $ (7,625 ) Segment data for the three months ended August 31, 2017 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 2,956 (394 ) 2,562 Cost of revenues (1,439 ) 95 (1,344 ) Research and development expenses, net (688 ) 299 (389 ) Operating expenses (1,641 ) (1,272 ) (2,913 ) Depreciation and amortization expense (945 ) - (945 ) Segment Performance $ (1,069 ) (1,960 ) - (3,029 ) Share-based compensation (108 ) (108 ) Financial income, net* 1,757 1,757 Share in losses of associated company (152 ) (152 ) Loss before income taxes 1,532 * Excluding $275 thousand stock based compensation included in financial income. Segment data for the three months ended August 31, 2016 is as follows: Corporate and CDMO CTB Eliminations Consolidated (in thousands) Revenues from external customers $ 1,852 $ $ (3 ) $ 1,849 Cost of revenues (1,748 ) 164 (1,584 ) Research and development expenses, net (565 ) (161 ) (726 ) Operating expenses (453 ) (448 ) (901 ) Depreciation and amortization expense (651 ) (1 ) (652 ) Segment Performance $ (1,000 ) $ (1,014 ) - (2,014 ) Share-based compensation (428 ) (428 ) Financial income (expenses), net (574 ) (574 ) Loss before income taxes $ (3,016 ) Geographic, Product and Customer Information Substantially all the Company's revenues and long-lived assets are located in Belgium through its controlled subsidiary MaSTherCell. Manufacturing activities show a significant increase of revenues in line with the company Business Plan. It reflects market recognition in CDMO business expertise and the adequacy of the Company strategy. Revenues from single customers from the CDMO segment that exceed 10% of total net revenues are: Three Months Ended Nine Months Ended August 31, August 31, August 31, August 31, 2016 2017 2016 2017 (in thousands) Customer A $ 852 $ 1,031 $ 2,813 $ 2,626 Customer B - 291 - 1,163 Customer C 809 1,904 Customer D $ 679 $ $ 1,637 $ CDMO business has substantially diversified revenues by source signing contracts with leading Biotech companies in their respective cell-based therapy field and strengthened its revenue base over the last three quarters. In January 2017, MaSTherCell entered into a service agreement with Les Laboratoires Servier ("Servier") for the development of its CAR-T cell therapy manufacturing platform and in June 2017, MaSTherCell entered into a service agreement with CRISPR Therapeutics AG ("CRISPR") for the development and manufacturing of allogeneic cell therapies. |
CONVERTIBLE LOAN AGREEMENTS
CONVERTIBLE LOAN AGREEMENTS | 9 Months Ended |
Aug. 31, 2017 | |
CONVERTIBLE LOAN AGREEMENTS [Text Block] | NOTE 4 – CONVERTIBLE LOAN AGREEMENTS (a) On January 12, 2017, the Company repaid the outstanding principal amount and accrued interest in the amount of $51 thousand on convertible loans that were issued during September 2016. The transaction had no material impact on the comprehensive loss for the period. (b) During the nine months ended August 31, 2017, the Company entered into several unsecured convertible note agreements with accredited or offshore investors for an aggregate amount of $3.95 million. The loans bear an annual interest rate of 6% and mature in two years from the date of issuance, unless converted earlier. The notes provide that the entire principal amount under the notes and accrued interest automatically convert into units as in the agreement upon the earlier to occur of any of the following: (i) the closing of an offering of equity securities of the Company with gross proceeds to the Company greater than $10 million (ii) the trading of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) on the over-the counter market or an exchange at a weighted average price of at least $0.52 (adjusted for certain capital events such as stock splits) for fifty (50) consecutive trading days, or (iii) the listing of the Company’s Common Stock on a U.S. National Exchange. Since the closing price of the Company’s publicly traded stock is greater than the effective conversion price on the closing date, the conversion feature is considered "beneficial" to the holders and equal to $2.24 million. The difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt. The transaction costs were approximately $405 thousand, out of which $129 thousand was the fair value of warrants for the purchase of 434,436 shares of Common Stock granted to three holders as a success fee, exercisable at $0.52 per share for three years. The fair value of those warrants as of the date of grant was evaluated using the Black-Scholes valuation model. (c) During the nine months ended August 31, 2017, the Company entered into several unsecured convertible note agreements with accredited or offshore investors for an aggregate amount of $0.8 million. The notes have 0% or 6% interest rate and are scheduled to mature between nine months and one year unless converted earlier. At any time, all or a portion of the outstanding principal amount and accrued but unpaid interest thereon may be converted at the Holder’s option into shares of the Company common stock at a price of $0.52 per share. The Company also issued to the investors three-year warrants to purchase up to 1,746,063 shares of the Company’s Common Stock at a per share exercise price of $0.52. Since the closing price of the Company’s publicly traded stock is greater than the effective conversion price on the measurement date, the conversion feature is considered "beneficial" to the holders and equal to $81 thousand. The difference is treated as issued equity and reduces the carrying value of the host debt; the discount is accreted as deemed interest on the debt. (d) On January 23, 2017, the Company and a Non-U.S. institutional investor, entered into an agreement pursuant to which the investor advanced to the Company $400,000 at per annum rate of 6% and with a maturity date of April 23, 2017. The transaction costs were approximately $71 thousand, out of which $35 thousand as stock based compensation due to issuance of 76,923 warrants and 32,051 shares. The fair value of those warrants as of the date of grant was evaluated by using the Black-Scholes valuation model. The principal amount and accrued interest were repaid by the Company on March 7, 2017 and, in accordance with the terms of the agreement, the Company issued to the investor 650,000 restricted shares of the Company’s Common Stock. The fair value of the shares as of March 7, 2017, was $494 thousand and was recorded as financial expenses. (e) In January 2017 MaSTherCell repaid all but one of its bondholders (originally issued on September 14, 2014), and the aggregate payment amounted to $1.7 million (€ 1.5 million). On January 17, 2017, the remaining bondholder agreed to extend the duration of his Convertible bond until March 21, 2017. In consideration for the extension, the Company issued to the bondholder warrants to purchase 102,822 shares of the Company’s Common Stock, exercisable over a three-year period at a per share exercise price of $0.52. The fair value of those warrants as of the date of grant was $20 thousand using the Black-Scholes valuation model. On March 20, 2017, the remaining bondholder agreed to convert his convertible bonds into 488,182 shares of the Company’s Common Stock. The Company returned to treasury from the escrow arrangement entered into in March 2015 in connection with the MaSTherCell acquisition a total of 3,157,716 consideration, in accordance with the terms of the MaSTherCell acquisition agreement. These shares have been retired and cancelled. (f) On February 27, 2017, the Company and Admiral Ventures Inc. (“Admiral”) entered into an agreement resolving the payment of amounts owed to Admiral. Under the terms of the settlement agreement, Admiral extended the maturity date to June 30, 2018. The Company agreed to pay to Admiral, on or before March 1, 2017, between $0.3 million and $1.5 million. Further, beginning April 2017, the Company agreed to make a monthly payment of $125 thousand on account of remaining unpaid balance, and also agreed to remit 25% of all amounts received from equity financing raised above $1 million and 20% of such amounts above $500 thousand on account of amounts owed. The Company accounted for the above changes as a modification of the old debt. On March 1 and July 17, 2017, the Company repaid $1.5 million and $125 thousand on account of the principal amount of the loan and accrued interest, respectively. As of August 31, 2017, the Company was in arrears in its payment obligations under such agreement. See also Note 10(c). |
COMMITMENTS
COMMITMENTS | 9 Months Ended |
Aug. 31, 2017 | |
COMMITMENTS [Text Block] | NOTE 5 – COMMITMENTS Grants In April 2016, the Belgian Subsidiary received the formal approval from the Walloon Region, Belgium (Service Public of Wallonia, DGO6) (“DGO6”) for a budgeted € 1.3 million ($1.5 million) support program for CTB activity. The financial support is awarded to the Belgian subsidiary Orgenesis as a recoverable advance payment at 55% of budgeted costs, or for a total of € 0.7 million thousand ($0.8 million). The grant will be paid over the project period. On December 19, 2016, the Belgian Subsidiary received a first payment of € 359 thousand ($374 thousand). On October 8, 2016, the Belgian subsidiary received the formal approval from the DGO6 for an additional budget of € 12.3 million ($12.8 million) support program for the GMP production of AIP cells for two clinical trials that will be performed in Germany and Belgium. The project will be held during a period of three years commencing January 1, 2017. The financial support is awarded to the Belgium subsidiary at 55% of budgeted costs, a total of € 6.8 million ($7 million). The grant will be paid over the project period. On December 19, 2016, the Belgian Subsidiary received a first payment of € 1.7 million ($1.8 million). |
EQUITY
EQUITY | 9 Months Ended |
Aug. 31, 2017 | |
EQUITY [Text Block] | NOTE 6 – EQUITY Financings 1) During the nine months ended August 31, 2017, the Company entered into definitive agreements with accredited and other qualified investors relating to a private placement (the “Private Placement”) of (i) 1,286,944 shares of the Company’s Common Stock and (ii) three year warrants to purchase up to an additional 1,286,944 shares of the Company’s Common Stock at a per share exercise price of $0.52 and $0.65 respectively. The purchased securities were issued pursuant to subscription agreements between the Company and the purchasers for aggregate proceeds to the Company of $699 thousand. The Company allocated the proceeds from the Private Placement based on the fair value of the warrants and the shares. The table below presents the fair value of the instruments issued as of the closing dates and the allocation of the proceeds: Total Fair Value (in thousands) Warrants component $ 251 Shares component 448 Total $ 699 2) In January 2017, the Company entered into definitive agreements with an institutional investor for the private placement of 30,769,231 units of the Company’s securities for aggregate subscription proceeds to the Company of $16 million at $0.52 price per unit. Each unit is comprised of one share of the Company’s Common Stock and a warrant, exercisable over a three-years period from the date of issuance, to purchase one additional share of Common Stock at a per share exercise price of $0.52. The subscription proceeds are payable on a periodic basis through August 2018. Each periodic payment of subscription proceeds will be evidenced by the Company’s standard securities subscription agreement. During the nine months ended August 31, 2017 the investor remitted to the Company $3.5 million, in consideration of which, the investor is entitled to 6,730,767 shares of the Company’s Common Stock and three-year warrants to purchase up to an additional 6,730,767 shares of the Company’s Common Stock at a per share exercise price of $0.52 The Company allocated the proceeds based on the fair value of the warrants and the shares. The table below presents the allocation of the proceeds as of the closing date: Total Fair Value (in thousands) Warrants component $ 1,207 Shares component 2,293 Total $ 3,500 As of August 31, 2017, 1,923,076 shares have not been issued therefore the Company recorded $624 thousand net of transaction costs in Receipts on Account of Shares to be Allotted. In connection therewith, the Company undertook to pay a fee of 5%, resulting in the payment of $175 thousand and the issuance of 336,538 restricted shares of Common Stock. The fair value of the shares as of the date of grant was $145 thousand using the share price on the date of grant. |
STOCK BASED COMPENSATION
STOCK BASED COMPENSATION | 9 Months Ended |
Aug. 31, 2017 | |
STOCK BASED COMPENSATION [Text Block] | NOTE 7 – STOCK BASED COMPENSATION a. Options Granted to Employees and Directors On December 9, 2016, the Company granted to the employees and directors 7,300,000 options and on and June 1, 2017, the Company granted to the Chief Executive Officer 1,000,000 options, which are summarized on the table below: No. of options granted Exercise price Vesting period Fair value at grant (in thousands) Expiration period Directors 2,000,000 $0.4 Quarterly vested $558 10 years Employees 5,300,000 $0.4 Quarterly vested $1,480 10 years Chief Executive 1,000,000 $0.6 Semi Annually $435 10 years The fair value of each stock option grant is estimated at the date of grant using a Black Scholes option pricing model. The volatility is based on historical volatility of the Company, by statistical analysis of the weekly share price for the last two years. The expected term is the mid-point between the vesting date and the maximum contractual term for each grant equal to the contractual life. The fair value of each option grant is based on the following assumptions: December 9, June 1, 2017 2016 Value of one common share $0.39 $0.62 Dividend yield 0% 0% Expected stock price volatility 94% 95% Risk free interest rate 1.89% 1.76% Expected term (years) 5 5 b. Options and Warrants Granted to a Consultants On December 9, 2016, the Company entered into a consulting agreements for the provision of professional services for a period of one year. Under the terms of the agreement, the Company granted to a consultants 200,000 options exercisable at $0.40 per share. The options are to vest quarterly over a period of one year. The fair value of those options as of the date of grant was $68 thousand using the Black-Scholes valuation model. |
LOSS PER SHARE
LOSS PER SHARE | 9 Months Ended |
Aug. 31, 2017 | |
LOSS PER SHARE [Text Block] | NOTE 8 – LOSS PER SHARE The following table sets forth the calculation of basic and diluted loss per share for the period indicated: Three Months Ended Nine Months Ended August 31, August 31, 2017 2016 2017 2016 (in thousands, except per share data) Basic: Loss for the period $ 1,953 $ 2,644 $ 11,511 $ 6,312 Weighted average number of common shares outstanding 123,349,597 111,188,616 113,725,909 108,784,862 Loss per common share $ 0.02 $ 0.02 $ 0.10 $ 0.06 Diluted Loss for the period $ 1,953 $ 2,644 $ 11,511 $ 6,312 Changes in fair value of embedded derivative and interest expense on convertible loans 238 137 87 Loss for the period $ 2,191 $ 2,644 $ 11,648 $ 6,399 Weighted average number of shares used in the computation of basic and diluted loss per share 123,349,597 111,188,616 113,725,909 108,704,862 Number of dilutive shares related to convertible loans 1,275,815 312,500 Weighted average number of common shares outstanding 124,625,412 111,188,616 114,038,409 108,704,862 Loss per common share $ 0.02 $ 0.02 $ 0.10 $ 0.06 Diluted loss per share does not include 52,510,273 shares underlying outstanding options and warrants and 29,551,172 shares upon conversion of convertible notes for the three and nine months ended August 31, 2017, because the effect of their inclusion in the computation would be anti-dilutive. Diluted loss per share does not include 16,954,564 shares underlying outstanding options, 20,971,190 shares issuable upon exercise of warrants, 800,000 shares due to stock-based compensation to service providers and 7,365,719 shares upon conversion of convertible notes for the nine and three months ended August 31, 2016, because the effect of their inclusion in the computation would be anti-dilutive. |
FAIR VALUE PRESENTATION
FAIR VALUE PRESENTATION | 9 Months Ended |
Aug. 31, 2017 | |
FAIR VALUE PRESENTATION [Text Block] | NOTE 9 - FAIR VALUE PRESENTATION The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below: • Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. • Level 2: Observable inputs that are based on inputs not quoted on active markets, but corroborated by market data. • Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs, to the extent possible, and considers credit risk in its assessment of fair value. As of August 31, 2017, and November 30, 2016, the Company’s liabilities that are measured at fair value and classified as level 3 fair value are as follows (in thousands): August 31, November 30, 2017 201 6 Level 3 Level 3 Warrants (1) $ 873 $ 1,843 Price protection derivative (1) - 76 Embedded derivatives convertible loans*(1) 20 240 Put option derivatives 273 273 Convertible bonds (2) $ - $ 1,818 * The embedded derivative is presented in the Company's balance sheets on a combined basis with the related host contract (the convertible loans). (1) The fair value of the warrants, price protection derivative and embedded derivatives is determined by using a Monte Carlo Simulation Model. This model, in contrast to a closed form model, such as the Black-Scholes Model, enables the Company to take into consideration the conversion price changes over the conversion period of the loan, and therefore is more appropriate in this case. (2) The fair value of the convertible bonds described in Note 7 of the Annual Report is determined by using a binomial model for the valuation of the embedded derivative and the fair value of the bond was calculated based on the effective rate on the valuation date ( 6%). The binomial model used the forecast of the Company share price during the convertible bond's contractual term. Since the convertible bond is in Euro and the model is in USD, the Company has used the Euro/USD forward rates for each period. In order to solve for the embedded derivative fair value, the calculation was performed as follows: • Stage A - The model calculates several potential future share prices of the Company based on the volatility and risk-free interest rate assumptions. • Stage B - the embedded derivative value is calculated "backwards" in a way that considers the maximum value between holding the bonds until maturity or converting the bonds. As of August 31, 2017, the convertible bonds have been repaid or converted see Note 4(e). The following table presents the assumptions that were used for the models as of August 31, 2017: Embedded Warrants Derivative Fair value of shares of Common Stock $ 0.32 $ 0.32 Expected volatility 92% 82% Discount on lack of marketability 13% - Risk free interest rate 1.25%- 1.31% 0.95%- 1.03% Expected term (years) 1.2 - 1.8 0.08 - 0.33 Expected dividend yield 0% 0% Expected capital raise dates October 31, 2017 - The fair value of the convertible bonds is equal to their principal amount and the aggregate accrued interest. The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the nine months ended August 31, 2017: Convertible Price Put Option Embedded Bonds Protection Derivative Warrants Derivatives Derivative (in thousands) Balance at beginning of the year $ 1,843 $ 240 $ 1,818 $ 76 $ 273 Changes in fair value during the period (970 ) 635 22 (76 ) Repayment and conversion of convertible bonds and convertible loan (855 ) (1,827 ) Translation adjustments (13 ) Balance at end of the period $ 873 $ 20 $ - $ - $ 273 There were no transfers to Level 3 during the nine months ended August 31, 2017. The table below sets forth a summary of the changes in the fair value of the Company’s financial liabilities classified as Level 3 for the year ended November 30, 2016: Convertible Price Put Option Embedded Bonds Protection Derivative Warrants Derivatives Derivative (in thousands) Balance at beginning of the year $ 1,382 $ 289 $ 1,888 $ 1,533 $ Additions 802 40 120 273 Conversion (10 ) Changes in fair value related to Price Protection Derivative expired* (108 ) Changes in fair value during the period (341 ) (87 ) (84 ) (1,469 ) Changes in fair value due to extinguishment of convertible loan 8 Translation adjustments 14 Balance at end of the year $ 1,843 $ 240 $ 1,818 $ 76 $ 273 (*) During the twelve months ended November 30, 2016, 11,732,916 Price Protection Derivative have expired. There were no transfers to Level 3 during the twelve months ended November 30, 2016. |
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS | 9 Months Ended |
Aug. 31, 2017 | |
SUBSEQUENT EVENTS [Text Block] | NOTE 10 - SUBSEQUENT EVENTS a. During September 2017, the Company entered into unsecured convertible note agreements with accredited or offshore investors for an aggregate amount of $0.6 million. The notes bear an annual interest rate of 6% and mature in two years from the closing date, unless earlier converted subject to the terms defined in the agreements. The notes provide that the entire principal amount under the notes and accrued interest automatically convert into units as in the agreement upon the earlier to occur of any of the following: (i) the closing of an offering of equity securities of the Company with gross proceeds to the Company greater than $10 million (ii) the trading of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) on the over-the counter market or an exchange at a weighted average price of at least $0.52 (adjusted for certain capital events such as stock splits) for fifty (50) consecutive trading days, or (iii) the listing of the Company’s Common Stock on a U.S. National Exchange. b. In October 2017, the institutional investor referred to in Note 6b, remitted to the Company $0.5 million in subscription proceeds entitling such investor to 961,538 shares of Common Stock and three year warrants for an additional 961,538 shares. As of October 16, 2017 the Company has received a total of $4 million out of the committed $16 million subscription proceeds. c. On September 29, 2017, the Company paid to Admiral $125 thousand on account of the debt owed. |
SEGMENT INFORMATION (Tables)
SEGMENT INFORMATION (Tables) | 3 Months Ended | 9 Months Ended | ||
Aug. 31, 2017 | Aug. 31, 2016 | Aug. 31, 2017 | Aug. 31, 2016 | |
Schedule of Segment Information [Table Text Block] | Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 2,956 (394 ) 2,562 Cost of revenues (1,439 ) 95 (1,344 ) Research and development expenses, net (688 ) 299 (389 ) Operating expenses (1,641 ) (1,272 ) (2,913 ) Depreciation and amortization expense (945 ) - (945 ) Segment Performance $ (1,069 ) (1,960 ) - (3,029 ) Share-based compensation (108 ) (108 ) Financial income, net* 1,757 1,757 Share in losses of associated company (152 ) (152 ) Loss before income taxes 1,532 | Corporate and CDMO CTB Eliminations Consolidated (in thousands) Revenues from external customers $ 1,852 $ $ (3 ) $ 1,849 Cost of revenues (1,748 ) 164 (1,584 ) Research and development expenses, net (565 ) (161 ) (726 ) Operating expenses (453 ) (448 ) (901 ) Depreciation and amortization expense (651 ) (1 ) (652 ) Segment Performance $ (1,000 ) $ (1,014 ) - (2,014 ) Share-based compensation (428 ) (428 ) Financial income (expenses), net (574 ) (574 ) Loss before income taxes $ (3,016 ) | Corporate and CDMO CTB Eliminations Consolidated (in thousands) Revenues from external customers $ 7,705 (993 ) $ 6,712 Cost of revenues (4,358 ) 403 (3,955 ) Research and development expenses, net (1,932 ) 590 (1,342 ) Operating expenses (916 ) (6,060 ) (6,976 ) Depreciation and amortization expenses (2,145 ) (7 ) (2,152 ) Segment Performance $ 286 (8,000 ) - (7,714 ) Stock-based compensation (2,817 ) (2,817 ) Financial expenses , net* (139 ) (139 ) Share in losses of associated company (348 ) (348 ) Loss before income taxes (11,018 ) | Corporate and CDMO CTB Eliminations Consolidated (in thousands) Net revenues from external customers $ 4,826 $ $ (325 ) $ 4,501 Cost of revenues (4,968 ) 463 (4,505 ) Research and development expenses, net (1,239 ) (138 ) (1,377 ) Operating expenses (1,518 ) (1,299 ) (2,817 ) Depreciation and amortization expense (1,984 ) (3 ) (1,987 ) Segment Performance $ (3,644 ) $ (2,541 ) - (6,185 ) Share-based compensation (2,085 ) (2,085 ) Financial income, net 645 645 Loss before income taxes $ (7,625 ) |
Schedule of Revenues from Major Customers [Table Text Block] | Three Months Ended Nine Months Ended August 31, August 31, August 31, August 31, 2016 2017 2016 2017 (in thousands) Customer A $ 852 $ 1,031 $ 2,813 $ 2,626 Customer B - 291 - 1,163 Customer C 809 1,904 Customer D $ 679 $ $ 1,637 $ |
EQUITY (Tables)
EQUITY (Tables) | 9 Months Ended |
Aug. 31, 2017 | |
Schedule of Fair Value of Private Placements [Table Text Block] | Total Fair Value (in thousands) Warrants component $ 251 Shares component 448 Total $ 699 |
Schedule of Fair Value of Warrants [Table Text Block] | Total Fair Value (in thousands) Warrants component $ 1,207 Shares component 2,293 Total $ 3,500 |
STOCK BASED COMPENSATION (Table
STOCK BASED COMPENSATION (Tables) | 9 Months Ended |
Aug. 31, 2017 | |
Employee Stock Ownership Plan (ESOP) Disclosures [Table Text Block] | No. of options granted Exercise price Vesting period Fair value at grant (in thousands) Expiration period Directors 2,000,000 $0.4 Quarterly vested $558 10 years Employees 5,300,000 $0.4 Quarterly vested $1,480 10 years Chief Executive 1,000,000 $0.6 Semi Annually $435 10 years |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | December 9, June 1, 2017 2016 Value of one common share $0.39 $0.62 Dividend yield 0% 0% Expected stock price volatility 94% 95% Risk free interest rate 1.89% 1.76% Expected term (years) 5 5 |
LOSS PER SHARE (Tables)
LOSS PER SHARE (Tables) | 9 Months Ended |
Aug. 31, 2017 | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended Nine Months Ended August 31, August 31, 2017 2016 2017 2016 (in thousands, except per share data) Basic: Loss for the period $ 1,953 $ 2,644 $ 11,511 $ 6,312 Weighted average number of common shares outstanding 123,349,597 111,188,616 113,725,909 108,784,862 Loss per common share $ 0.02 $ 0.02 $ 0.10 $ 0.06 Diluted Loss for the period $ 1,953 $ 2,644 $ 11,511 $ 6,312 Changes in fair value of embedded derivative and interest expense on convertible loans 238 137 87 Loss for the period $ 2,191 $ 2,644 $ 11,648 $ 6,399 Weighted average number of shares used in the computation of basic and diluted loss per share 123,349,597 111,188,616 113,725,909 108,704,862 Number of dilutive shares related to convertible loans 1,275,815 312,500 Weighted average number of common shares outstanding 124,625,412 111,188,616 114,038,409 108,704,862 Loss per common share $ 0.02 $ 0.02 $ 0.10 $ 0.06 |
FAIR VALUE PRESENTATION (Tables
FAIR VALUE PRESENTATION (Tables) | 9 Months Ended | 12 Months Ended |
Aug. 31, 2017 | Nov. 30, 2016 | |
Schedule of Assets and Liabilities at Fair Value [Table Text Block] | August 31, November 30, 2017 201 6 Level 3 Level 3 Warrants (1) $ 873 $ 1,843 Price protection derivative (1) - 76 Embedded derivatives convertible loans*(1) 20 240 Put option derivatives 273 273 Convertible bonds (2) $ - $ 1,818 | |
Schedule of Fair Value, Assumptions Used [Table Text Block] | Embedded Warrants Derivative Fair value of shares of Common Stock $ 0.32 $ 0.32 Expected volatility 92% 82% Discount on lack of marketability 13% - Risk free interest rate 1.25%- 1.31% 0.95%- 1.03% Expected term (years) 1.2 - 1.8 0.08 - 0.33 Expected dividend yield 0% 0% Expected capital raise dates October 31, 2017 - | |
Schedule of Fair Value of Financial Liabilities, Activity [Table Text Block] | Convertible Price Put Option Embedded Bonds Protection Derivative Warrants Derivatives Derivative (in thousands) Balance at beginning of the year $ 1,843 $ 240 $ 1,818 $ 76 $ 273 Changes in fair value during the period (970 ) 635 22 (76 ) Repayment and conversion of convertible bonds and convertible loan (855 ) (1,827 ) Translation adjustments (13 ) Balance at end of the period $ 873 $ 20 $ - $ - $ 273 | Convertible Price Put Option Embedded Bonds Protection Derivative Warrants Derivatives Derivative (in thousands) Balance at beginning of the year $ 1,382 $ 289 $ 1,888 $ 1,533 $ Additions 802 40 120 273 Conversion (10 ) Changes in fair value related to Price Protection Derivative expired* (108 ) Changes in fair value during the period (341 ) (87 ) (84 ) (1,469 ) Changes in fair value due to extinguishment of convertible loan 8 Translation adjustments 14 Balance at end of the year $ 1,843 $ 240 $ 1,818 $ 76 $ 273 |
GENERAL AND BASIS OF PRESENTA21
GENERAL AND BASIS OF PRESENTATION (Narrative) (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
General And Basis Of Presentation 1 | $ 41,000,000 |
General And Basis Of Presentation 2 | 12,000,000 |
General And Basis Of Presentation 3 | 16,000,000 |
General And Basis Of Presentation 4 | 6,100,000 |
General And Basis Of Presentation 5 | 9,000,000 |
General And Basis Of Presentation 6 | 3.5 |
General And Basis Of Presentation 7 | 16,000,000 |
General And Basis Of Presentation 8 | 1,100,000 |
General And Basis Of Presentation 9 | $ 1,000,000 |
SEGMENT INFORMATION (Narrative)
SEGMENT INFORMATION (Narrative) (Details) $ in Thousands | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Segment Information 1 | $ 1,389 |
Segment Information 2 | $ 275 |
Segment Information 3 | 10.00% |
CONVERTIBLE LOAN AGREEMENTS (Na
CONVERTIBLE LOAN AGREEMENTS (Narrative) (Details) - 9 months ended Aug. 31, 2017 $ / shares in Units, € in Millions | USD ($)$ / sharesshares | EUR (€)shares |
Convertible Loan Agreements 1 | $ 51,000 | |
Convertible Loan Agreements 2 | $ 3,950,000 | |
Convertible Loan Agreements 3 | 6.00% | 6.00% |
Convertible Loan Agreements 4 | $ 10,000,000 | |
Convertible Loan Agreements 5 | $ / shares | $ 0.0001 | |
Convertible Loan Agreements 6 | $ 0.52 | |
Convertible Loan Agreements 7 | 2,240,000 | |
Convertible Loan Agreements 8 | 405,000 | |
Convertible Loan Agreements 9 | $ 129,000 | |
Convertible Loan Agreements 10 | shares | 434,436 | 434,436 |
Convertible Loan Agreements 11 | $ / shares | $ 0.52 | |
Convertible Loan Agreements 12 | $ 800,000 | |
Convertible Loan Agreements 13 | 0.00% | 0.00% |
Convertible Loan Agreements 14 | 6.00% | 6.00% |
Convertible Loan Agreements 15 | $ / shares | $ 0.52 | |
Convertible Loan Agreements 16 | shares | 1,746,063 | 1,746,063 |
Convertible Loan Agreements 17 | $ 0.52 | |
Convertible Loan Agreements 18 | 81,000 | |
Convertible Loan Agreements 19 | $ 400,000 | |
Convertible Loan Agreements 20 | 6.00% | 6.00% |
Convertible Loan Agreements 21 | $ 71,000 | |
Convertible Loan Agreements 22 | $ 35,000 | |
Convertible Loan Agreements 23 | shares | 76,923 | 76,923 |
Convertible Loan Agreements 24 | shares | 32,051 | 32,051 |
Convertible Loan Agreements 25 | shares | 650,000 | 650,000 |
Convertible Loan Agreements 26 | $ 494,000 | |
Convertible Loan Agreements 27 | $ 1,700,000 | |
Convertible Loan Agreements 28 | € | € 1.5 | |
Convertible Loan Agreements 29 | shares | 102,822 | 102,822 |
Convertible Loan Agreements 30 | $ 0.52 | |
Convertible Loan Agreements 31 | $ 20,000 | |
Convertible Loan Agreements 32 | shares | 488,182 | 488,182 |
Convertible Loan Agreements 33 | 3,157,716 | 3,157,716 |
Convertible Loan Agreements 34 | $ 300,000 | |
Convertible Loan Agreements 35 | 1,500,000 | |
Convertible Loan Agreements 36 | $ 125,000 | |
Convertible Loan Agreements 37 | 25.00% | 25.00% |
Convertible Loan Agreements 38 | $ 1,000,000 | |
Convertible Loan Agreements 39 | 20.00% | 20.00% |
Convertible Loan Agreements 40 | $ 500,000 | |
Convertible Loan Agreements 41 | 1,500,000 | |
Convertible Loan Agreements 42 | $ 125,000 |
COMMITMENTS (Narrative) (Detail
COMMITMENTS (Narrative) (Details) € in Thousands, $ in Thousands | 9 Months Ended | |
Aug. 31, 2017USD ($) | Aug. 31, 2017EUR (€) | |
Commitments 1 | € | € 1,300 | |
Commitments 2 | $ | $ 1,500 | |
Commitments 3 | 55.00% | 55.00% |
Commitments 4 | € | € 700 | |
Commitments 5 | $ | $ 800 | |
Commitments 6 | € | 359 | |
Commitments 7 | $ | 374 | |
Commitments 8 | € | € 12,300 | |
Commitments 9 | $ | $ 12,800 | |
Commitments 10 | 55.00% | 55.00% |
Commitments 11 | € | € 6,800 | |
Commitments 12 | $ | $ 7,000 | |
Commitments 13 | € | € 1,700 | |
Commitments 14 | $ | $ 1,800 |
EQUITY (Narrative) (Details)
EQUITY (Narrative) (Details) | 9 Months Ended |
Aug. 31, 2017USD ($)shares | |
Equity 1 | shares | 1,286,944 |
Equity 2 | shares | 1,286,944 |
Equity 3 | $ 0.52 |
Equity 4 | 0.65 |
Equity 5 | $ 699,000 |
Equity 6 | shares | 30,769,231 |
Equity 7 | $ 16,000,000 |
Equity 8 | 0.52 |
Equity 9 | 0.52 |
Equity 10 | $ 3,500,000 |
Equity 11 | shares | 6,730,767 |
Equity 12 | shares | 6,730,767 |
Equity 13 | $ 0.52 |
Equity 14 | shares | 1,923,076 |
Equity 15 | $ 624,000 |
Equity 16 | 5.00% |
Equity 17 | $ 175,000 |
Equity 18 | shares | 336,538 |
Equity 19 | $ 145,000 |
STOCK BASED COMPENSATION (Narra
STOCK BASED COMPENSATION (Narrative) (Details) $ / shares in Units, $ in Thousands | 9 Months Ended |
Aug. 31, 2017USD ($)$ / sharesshares | |
Stock Based Compensation 1 | 7,300,000 |
Stock Based Compensation 2 | 1,000,000 |
Stock Based Compensation 3 | 200,000 |
Stock Based Compensation 4 | $ / shares | $ 0.40 |
Stock Based Compensation 5 | $ | $ 68 |
LOSS PER SHARE (Narrative) (Det
LOSS PER SHARE (Narrative) (Details) | 9 Months Ended |
Aug. 31, 2017shares | |
Loss Per Share 1 | 52,510,273 |
Loss Per Share 2 | 29,551,172 |
Loss Per Share 3 | 16,954,564 |
Loss Per Share 4 | 20,971,190 |
Loss Per Share 5 | 800,000 |
Loss Per Share 6 | 7,365,719 |
FAIR VALUE PRESENTATION (Narrat
FAIR VALUE PRESENTATION (Narrative) (Details) | 9 Months Ended |
Aug. 31, 2017 | |
Fair Value Presentation 1 | 6.00% |
Fair Value Presentation 2 | 11,732,916 |
SUBSEQUENT EVENTS (Narrative) (
SUBSEQUENT EVENTS (Narrative) (Details) | 9 Months Ended |
Aug. 31, 2017USD ($)$ / sharesshares | |
Subsequent Events 1 | $ 600,000 |
Subsequent Events 2 | 6.00% |
Subsequent Events 3 | $ 10,000,000 |
Subsequent Events 4 | $ / shares | $ 0.0001 |
Subsequent Events 5 | $ 0.52 |
Subsequent Events 6 | $ 500,000 |
Subsequent Events 7 | shares | 961,538 |
Subsequent Events 8 | shares | 961,538 |
Subsequent Events 9 | $ 4,000,000 |
Subsequent Events 10 | 16,000,000 |
Subsequent Events 11 | $ 125,000 |
Schedule of Segment Information
Schedule of Segment Information (Details) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Aug. 31, 2017 | Aug. 31, 2016 | Aug. 31, 2017 | Aug. 31, 2016 | |
Segment Information Schedule Of Segment Information 1 | $ 7,705 | |||
Segment Information Schedule Of Segment Information 2 | (993) | |||
Segment Information Schedule Of Segment Information 3 | 6,712 | |||
Segment Information Schedule Of Segment Information 4 | (4,358) | |||
Segment Information Schedule Of Segment Information 5 | 403 | |||
Segment Information Schedule Of Segment Information 6 | (3,955) | |||
Segment Information Schedule Of Segment Information 7 | (1,932) | |||
Segment Information Schedule Of Segment Information 8 | 590 | |||
Segment Information Schedule Of Segment Information 9 | (1,342) | |||
Segment Information Schedule Of Segment Information 10 | (916) | |||
Segment Information Schedule Of Segment Information 11 | (6,060) | |||
Segment Information Schedule Of Segment Information 12 | (6,976) | |||
Segment Information Schedule Of Segment Information 13 | (2,145) | |||
Segment Information Schedule Of Segment Information 14 | (7) | |||
Segment Information Schedule Of Segment Information 15 | (2,152) | |||
Segment Information Schedule Of Segment Information 16 | 286 | |||
Segment Information Schedule Of Segment Information 17 | (8,000) | |||
Segment Information Schedule Of Segment Information 18 | 0 | |||
Segment Information Schedule Of Segment Information 19 | (7,714) | |||
Segment Information Schedule Of Segment Information 20 | (2,817) | |||
Segment Information Schedule Of Segment Information 21 | (2,817) | |||
Segment Information Schedule Of Segment Information 22 | (139) | |||
Segment Information Schedule Of Segment Information 23 | (139) | |||
Segment Information Schedule Of Segment Information 24 | (348) | |||
Segment Information Schedule Of Segment Information 25 | (348) | |||
Segment Information Schedule Of Segment Information 26 | $ (11,018) | |||
Segment Information Schedule Of Segment Information 1 | $ 4,826 | |||
Segment Information Schedule Of Segment Information 2 | (325) | |||
Segment Information Schedule Of Segment Information 3 | 4,501 | |||
Segment Information Schedule Of Segment Information 4 | (4,968) | |||
Segment Information Schedule Of Segment Information 5 | 463 | |||
Segment Information Schedule Of Segment Information 6 | (4,505) | |||
Segment Information Schedule Of Segment Information 7 | (1,239) | |||
Segment Information Schedule Of Segment Information 8 | (138) | |||
Segment Information Schedule Of Segment Information 9 | (1,377) | |||
Segment Information Schedule Of Segment Information 10 | (1,518) | |||
Segment Information Schedule Of Segment Information 11 | (1,299) | |||
Segment Information Schedule Of Segment Information 12 | (2,817) | |||
Segment Information Schedule Of Segment Information 13 | (1,984) | |||
Segment Information Schedule Of Segment Information 14 | (3) | |||
Segment Information Schedule Of Segment Information 15 | (1,987) | |||
Segment Information Schedule Of Segment Information 16 | (3,644) | |||
Segment Information Schedule Of Segment Information 17 | (2,541) | |||
Segment Information Schedule Of Segment Information 18 | 0 | |||
Segment Information Schedule Of Segment Information 19 | (6,185) | |||
Segment Information Schedule Of Segment Information 20 | (2,085) | |||
Segment Information Schedule Of Segment Information 21 | (2,085) | |||
Segment Information Schedule Of Segment Information 22 | 645 | |||
Segment Information Schedule Of Segment Information 23 | 645 | |||
Segment Information Schedule Of Segment Information 24 | $ (7,625) | |||
Segment Information Schedule Of Segment Information 1 | $ 2,956 | |||
Segment Information Schedule Of Segment Information 2 | (394) | |||
Segment Information Schedule Of Segment Information 3 | 2,562 | |||
Segment Information Schedule Of Segment Information 4 | (1,439) | |||
Segment Information Schedule Of Segment Information 5 | 95 | |||
Segment Information Schedule Of Segment Information 6 | (1,344) | |||
Segment Information Schedule Of Segment Information 7 | (688) | |||
Segment Information Schedule Of Segment Information 8 | 299 | |||
Segment Information Schedule Of Segment Information 9 | (389) | |||
Segment Information Schedule Of Segment Information 10 | (1,641) | |||
Segment Information Schedule Of Segment Information 11 | (1,272) | |||
Segment Information Schedule Of Segment Information 12 | (2,913) | |||
Segment Information Schedule Of Segment Information 13 | (945) | |||
Segment Information Schedule Of Segment Information 14 | 0 | |||
Segment Information Schedule Of Segment Information 15 | (945) | |||
Segment Information Schedule Of Segment Information 16 | (1,069) | |||
Segment Information Schedule Of Segment Information 17 | (1,960) | |||
Segment Information Schedule Of Segment Information 18 | 0 | |||
Segment Information Schedule Of Segment Information 19 | (3,029) | |||
Segment Information Schedule Of Segment Information 20 | (108) | |||
Segment Information Schedule Of Segment Information 21 | (108) | |||
Segment Information Schedule Of Segment Information 22 | 1,757 | |||
Segment Information Schedule Of Segment Information 23 | 1,757 | |||
Segment Information Schedule Of Segment Information 24 | (152) | |||
Segment Information Schedule Of Segment Information 25 | (152) | |||
Segment Information Schedule Of Segment Information 26 | $ 1,532 | |||
Segment Information Schedule Of Segment Information 1 | $ 1,852 | |||
Segment Information Schedule Of Segment Information 2 | (3) | |||
Segment Information Schedule Of Segment Information 3 | 1,849 | |||
Segment Information Schedule Of Segment Information 4 | (1,748) | |||
Segment Information Schedule Of Segment Information 5 | 164 | |||
Segment Information Schedule Of Segment Information 6 | (1,584) | |||
Segment Information Schedule Of Segment Information 7 | (565) | |||
Segment Information Schedule Of Segment Information 8 | (161) | |||
Segment Information Schedule Of Segment Information 9 | (726) | |||
Segment Information Schedule Of Segment Information 10 | (453) | |||
Segment Information Schedule Of Segment Information 11 | (448) | |||
Segment Information Schedule Of Segment Information 12 | (901) | |||
Segment Information Schedule Of Segment Information 13 | (651) | |||
Segment Information Schedule Of Segment Information 14 | (1) | |||
Segment Information Schedule Of Segment Information 15 | (652) | |||
Segment Information Schedule Of Segment Information 16 | (1,000) | |||
Segment Information Schedule Of Segment Information 17 | (1,014) | |||
Segment Information Schedule Of Segment Information 18 | 0 | |||
Segment Information Schedule Of Segment Information 19 | (2,014) | |||
Segment Information Schedule Of Segment Information 20 | (428) | |||
Segment Information Schedule Of Segment Information 21 | (428) | |||
Segment Information Schedule Of Segment Information 22 | (574) | |||
Segment Information Schedule Of Segment Information 23 | (574) | |||
Segment Information Schedule Of Segment Information 24 | $ (3,016) |
Schedule of Revenues from Major
Schedule of Revenues from Major Customers (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Segment Information Schedule Of Revenues From Major Customers 1 | $ 852 |
Segment Information Schedule Of Revenues From Major Customers 2 | 1,031 |
Segment Information Schedule Of Revenues From Major Customers 3 | 2,813 |
Segment Information Schedule Of Revenues From Major Customers 4 | 2,626 |
Segment Information Schedule Of Revenues From Major Customers 5 | 0 |
Segment Information Schedule Of Revenues From Major Customers 6 | 291 |
Segment Information Schedule Of Revenues From Major Customers 7 | 0 |
Segment Information Schedule Of Revenues From Major Customers 8 | 1,163 |
Segment Information Schedule Of Revenues From Major Customers 9 | 809 |
Segment Information Schedule Of Revenues From Major Customers 10 | 1,904 |
Segment Information Schedule Of Revenues From Major Customers 11 | 679 |
Segment Information Schedule Of Revenues From Major Customers 12 | $ 1,637 |
Schedule of Fair Value of Priva
Schedule of Fair Value of Private Placements (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Equity Schedule Of Fair Value Of Private Placements 1 | $ 251 |
Equity Schedule Of Fair Value Of Private Placements 2 | 448 |
Equity Schedule Of Fair Value Of Private Placements 3 | $ 699 |
Schedule of Fair Value of Warra
Schedule of Fair Value of Warrants (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Equity Schedule Of Fair Value Of Warrants 1 | $ 1,207 |
Equity Schedule Of Fair Value Of Warrants 2 | 2,293 |
Equity Schedule Of Fair Value Of Warrants 3 | $ 3,500 |
Employee Stock Ownership Plan (
Employee Stock Ownership Plan (ESOP) Disclosures (Details) | 9 Months Ended |
Aug. 31, 2017USD ($)yr | |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 1 | $ 2,000,000 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 2 | $ 0.4 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 3 | yr | 2 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 4 | $ 558 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 5 | yr | 10 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 6 | $ 5,300,000 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 7 | $ 0.4 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 8 | yr | 4 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 9 | $ 1,480 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 10 | yr | 10 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 11 | $ 1,000,000 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 12 | 0.6 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 13 | $ 435 |
Stock Based Compensation Employee Stock Ownership Plan (esop) Disclosures 14 | yr | 10 |
Schedule of Share-based Payment
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1 | $ 0.39 |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2 | $ 0.62 |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3 | 0.00% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4 | 0.00% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 | 94.00% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 | 95.00% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7 | 1.89% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8 | 1.76% |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9 | $ 5 |
Stock Based Compensation Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10 | $ 5 |
Schedule of Earnings Per Share,
Schedule of Earnings Per Share, Basic and Diluted (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 1 | $ 1,953 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 2 | 2,644 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 3 | 11,511 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 4 | 6,312 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 5 | 123,349,597 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 6 | 111,188,616 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 7 | 113,725,909 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 8 | $ 108,784,862 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 9 | 0.02 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 10 | 0.02 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 11 | 0.10 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 12 | 0.06 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 13 | $ 1,953 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 14 | 2,644 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 15 | 11,511 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 16 | 6,312 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 17 | 238 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 18 | 137 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 19 | 87 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 20 | 2,191 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 21 | 2,644 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 22 | 11,648 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 23 | 6,399 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 24 | 123,349,597 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 25 | 111,188,616 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 26 | 113,725,909 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 27 | 108,704,862 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 28 | 1,275,815 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 29 | 312,500 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 30 | 124,625,412 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 31 | 111,188,616 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 32 | 114,038,409 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 33 | $ 108,704,862 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 34 | 0.02 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 35 | 0.02 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 36 | 0.10 |
Loss Per Share Schedule Of Earnings Per Share, Basic And Diluted 37 | 0.06 |
Schedule of Assets and Liabilit
Schedule of Assets and Liabilities at Fair Value (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 1 | $ 873 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 2 | 1,843 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 3 | 0 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 4 | 76 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 5 | 20 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 6 | 240 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 7 | 273 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 8 | 273 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 9 | 0 |
Fair Value Presentation Schedule Of Assets And Liabilities At Fair Value 10 | $ 1,818 |
Schedule of Fair Value, Assumpt
Schedule of Fair Value, Assumptions Used (Details) | 9 Months Ended |
Aug. 31, 2017USD ($) | |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 1 | 0.32 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 2 | 0.32 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 3 | 92.00% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 4 | 82.00% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 5 | 13.00% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 6 | $ 0 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 7 | 1.25% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 8 | 1.31% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 9 | 0.95% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 10 | 1.03% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 11 | 1.2 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 12 | 1.8 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 13 | 0.08 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 14 | 0.33 |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 15 | 0.00% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 16 | 0.00% |
Fair Value Presentation Schedule Of Fair Value, Assumptions Used 17 | $ 0 |
Schedule of Fair Value of Finan
Schedule of Fair Value of Financial Liabilities, Activity (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Aug. 31, 2017 | Nov. 30, 2016 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1 | $ 1,843 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2 | 240 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3 | 1,818 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4 | 76 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5 | 273 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6 | (970) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7 | 635 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8 | 22 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9 | (76) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10 | (855) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11 | (1,827) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12 | (13) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13 | 873 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14 | 20 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15 | 0 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16 | 0 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 17 | $ 273 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 1 | $ 1,382 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 2 | 289 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 3 | 1,888 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 4 | 1,533 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 5 | 802 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 6 | 40 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 7 | 120 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 8 | 273 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 9 | (10) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 10 | (108) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 11 | (341) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 12 | (87) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 13 | (84) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 14 | (1,469) | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 15 | 8 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 16 | 14 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 17 | 1,843 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 18 | 240 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 19 | 1,818 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 20 | 76 | |
Fair Value Presentation Schedule Of Fair Value Of Financial Liabilities, Activity 21 | $ 273 |